27670-94-6

Basic information

• Product Name: VitaminK2(35)0.13%Powder
• Synonyms: Vitamin K2(35),MK7 0.13% Powder;Vitamin K2(35),MK-7;VitaminK2(35)0.13%Powder;VitaminK2(35)1.3%Oil;VitaminK2(35)1.3%Powder;VitaminK2(35)0.13%Oil;Vitamin K2(35),MK7 0.13% Oil;Vitamin K2,MK7,menaquinone, menaquinon-7, menatetrenone, menatetren, menatetrenona, menatetrenonum
• CAS NO: 27670-94-6
• Molecular Formula: C46H64O2
• Molecular Weight: 649.00
• Product Categories: Health & Beauty;Vitamins and derivatives
• Mol File: 27670-94-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: VitaminK2(35)0.13%Powder(CAS DataBase Reference)
• NIST Chemistry Reference: VitaminK2(35)0.13%Powder(27670-94-6)
• EPA Substance Registry System: VitaminK2(35)0.13%Powder(27670-94-6)

Safety Data

• Hazardous Substances Data: 27670-94-6(Hazardous Substances Data)

Usage

General Description

Vitamin K2 (35) 0.13% Powder is a dietary supplement that contains vitamin K2, a fat-soluble vitamin that plays a crucial role in bone health and blood clotting. Vitamin K2 is essential for the proper functioning of proteins that are involved in bone mineralization and blood coagulation. This particular product contains 0.13% of vitamin K2, which makes it a concentrated form of the vitamin. It is commonly used as a dietary supplement to support bone health and overall well-being.

Upstream product

• 4128-17-0 (2E,6E)-farnesyl acetate 
• 93787-91-8 E,E,E-12-hydroxyfarnesyl acetate 
• 1597486-72-0 (2E,6E,10E)-3,7,11-trimethyl-12-(phenylsulfonyl)-dodeca-2,6,10-trien-1-yl acetate 
• 24163-93-7 farnesyl bromide 
• 1597487-01-8 C₃₈H₅₆O₄S 
• 1597486-78-6 (2E,6E,10E,14E,18E)-3,7,11,15,19,23-hexamethyl-12-(phenylsulfonyl)tetracosa-2,6,10,14,18,22-hexaen-1-ol 
• 104423-44-1 (2E,6E,10E)-12-bromo-3,7,11-trimethyl-2,6,10-dodecatrienyl acetate 
• 68778-93-8 (2E,6E,10E,14E,18E)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-ol 
• 74610-00-7 1-bromo-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene 
• 1597486-86-6 phenylsulfonyl hexaprenyl bromide 
• 1597486-87-7 C₆₂H₈₂O₆S₂ 
• 1597486-88-8 C₅₀H₇₄O₂ 
• 1597486-91-3 C₅₆H₇₈O₄S 
• 40266-21-5 (2E,6E,10E)-3,7,11-trimethyl-12-oxododeca-2,6,10-trien-1-yl acetate 

Downstream Products

• 1453189-02-0 3-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-4-hydroxy-2-methylnaphthalen-1-yl benzoate 
• 1453189-03-1 4-((diethoxyphosphoryl)oxy)-2-((2E,6E, 10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-3-methylnaphthalen-1-yl benzoate 
• 1453189-04-2 4-((diethoxyphosphoryl)oxy)-3-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-2-methylnaphthalen-1-yl benzoate 
• 1453189-05-3 4-(((tert-butoxycarbonyl)glycyl)oxy)-2-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-3-methylnaphthalen-1-yl benzoate 
• 1453189-06-4 4-(((tert-butoxycarbonyl)-L-valyl)oxy)-2-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-3-methylnaphthalen-1-yl benzoate 
• 1453189-01-9 2-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-4-hydroxy-3-methylnaphthalen-1-yl benzoate 
• 1453189-14-4 2-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10,14,18,22,26-heptaen-1-yl)-3-methylnaphthalene-1,4-diyl bis(4-(trifluoromethyl)benzoate) 
• 1453189-00-8 2-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyl-octacosa-2,6,10,14,18,22,26-heptaen-1-yl)-3-methylnaphthalene-1,4-diyl dibenzoate 
• 39776-47-1 menaquinol 

Relevant articles and documents

PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION

The invention relates to an improved process of vitamin K2 derivatives preparation via the alkylation of the menadione-cyclopentadiene adduct.

PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION

Provided is an improved process of vitamin K2 derivatives preparation, represented by formula (I) wherein n is an integer from 3 to 13.

Convergent synthesis of menaquinone-7 (MK-7)

A practical synthesis of menaquinone-7 (MK-7, vitamin K2) in the all-Trans form was designed. Stereoselective synthesis of MK-7 was achieved through a "1 + 6" convergent strategy by condensation of two building blocks, menadione monoprenyl derivative (fragment "1") with hexaprenyl bromide (fragment "6", 82%). Pd-catalyzed desulfonation with LiEt3BH (78%) was followed by oxidation of the hydroquinone moiety using ammonium cerium(IV) nitrate (72%). The major challenge in our methodology was the preparation of all-Trans hexaprenyl bromide by coupling of two triprenyl units derived from trans,trans-farnesol. Manufacturing on a pilot scale was accomplished through our approach. The scalable method was designed especially for a large, kilogram-scale production from easily available intermediates. Furthermore, the proposed methodology avoids many chromatographic purifications and allows for a relatively cost-effective manufacturing. Moreover, our synthesis yielded high-purity (99.9%) final product MK-7, which can be used as a dietary supplement as well as an active pharmaceutical ingredient.